Publication details

Cisplatin or LA-12 enhance killing effects of TRAIL in prostate cancer cells through Bid-dependent stimulation of mitochondrial apoptotic pathway but not caspase-10

Authors

BLANAROVA O. ŠAFAŘÍKOVÁ Barbora HERŮDKOVÁ Jarmila KRKOŠKA Martin TOMANKOVA S. KAHOUNOVA Z. ANDERA L. BOUCHAL J. KHARAISHVILI G. KRAL M. SOVA P. KOZUBÍK Alois HYRŠLOVÁ VACULOVÁ A.

Year of publication 2017
Type Article in Periodical
Magazine / Source Plos one
MU Faculty or unit

Faculty of Science

Citation
Doi http://dx.doi.org/10.1371/journal.pone.0188584
Keywords X-LINKED INHIBITOR; PLATINUM(IV) COMPLEX LA-12; CYTOCHROME-C; ANTITUMOR EFFICACY; IN-VITRO; DEATH; LIGAND; THERAPY; PROTEIN; MANNER
Description Searching for new strategies for effective elimination of human prostate cancer cells, we investigated the cooperative cytotoxic action of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and two platinum-based complexes, cisplatin or LA-12, and related molecular mechanisms. We demonstrated a notable ability of cisplatin or LA-12 to enhance the sensitivity of several human prostate cancer cell lines to TRAIL-induced cell death via an engagement of mitochondrial apoptotic pathway. This was accompanied by augmented Bid cleavage, Bak activation, loss of mitochondrial membrane potential, activation of caspase-8, -10, -9, and -3, and XIAP cleavage. RNAi-mediated silencing of Bid or Bak in Bax-deficient DU 145 cells suppressed the drug combination-induced cytotoxicity, further underscoring the involvement of mitochondrial signaling. The caspase-10 was dispensable for enhancement of cisplatin/LA-12 and TRAIL combination-induced cell death and stimulation of Bid cleavage. Importantly, we newly demonstrated LA-12-mediated enhancement of TRAIL-induced cell death in cancer cells derived from human patient prostate tumor specimens. Our results provide convincing evidence that employing TRAIL combined with cisplatin/LA-12 could contribute to more effective killing of prostate cancer cells compared to the individual action of the drugs, and offer new mechanistic insights into their cooperative anticancer action.